Table Graph
      published meta-analysis   sensitivity analysis   studies

remdesivir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsGS-US-540-5774, 10 days, 2020 0.77 [0.17; 3.50] GS-US-540-5774, 5 days, 2020 0.52 [0.09; 2.86] Mahajan, 2021 1.23 [0.34; 4.42] NIH NIAID ACTT-1, 2020 0.73 [0.52; 1.03] 0.75[0.54; 1.03]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, NIH NIAID ACTT-1, 202040%1,928moderatenot evaluable deathsdetailed resultsCAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] GS-US-540-5773 (Goldman), 2020 (REV) 1.37 [0.69; 2.72] GS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] Mahajan, 2021 1.23 [0.34; 4.42] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11] 0.88[0.68; 1.14]CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020727%8,024moderatenot evaluable deaths (time to event analysis only)detailed resultsGS-US-540-5774, 10 days, 2020 0.76 [0.17; 3.40] GS-US-540-5774, 5 days, 2020 0.51 [0.09; 2.84] NIH NIAID ACTT-1, 2020 0.55 [0.36; 0.84] SOLIDARITY (remdesivir), 2020 0.95 [0.81; 1.11] 0.75[0.50; 1.12]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 2020, SOLIDARITY (remdesivir), 2020452%7,309moderatenot evaluable clinical deteriorationdetailed resultsCAP-China (Wang et al.), 2020 0.95 [0.55; 1.64] 0.95[0.55; 1.64]CAP-China (Wang et al.), 202010%237NAnot evaluable clinical improvementdetailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] GS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63] GS-US-540-5774, 10 days, 2020 1.16 [0.77; 1.74] GS-US-540-5774, 5 days, 2020 1.65 [1.09; 2.49] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] 1.29[1.16; 1.44]CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 202050%2,492moderatenot evaluable clinical improvement (14-day)detailed resultsCAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] GS-US-540-5773 (Goldman), 2020 (REV) 0.65 [0.44; 0.98] GS-US-540-5774, 10 days, 2020 1.58 [1.01; 2.47] GS-US-540-5774, 5 days, 2020 1.56 [1.00; 2.44] 1.17[0.74; 1.85]CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020473%1,417moderatenot evaluable clinical improvement (28-day)detailed resultsCAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] GS-US-540-5774, 10 days, 2020 1.88 [1.03; 3.42] GS-US-540-5774, 5 days, 2020 1.75 [0.97; 3.17] NIH NIAID ACTT-1, 2020 1.35 [1.03; 1.76] 1.45[1.18; 1.79]CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 202040%2,082moderatenot evaluable clinical improvement (7-day)detailed resultsCAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] GS-US-540-5773 (Goldman), 2020 (REV) 0.69 [0.45; 1.05] GS-US-540-5774, 10 days, 2020 1.03 [0.69; 1.53] GS-US-540-5774, 5 days, 2020 1.41 [0.94; 2.09] 1.00[0.70; 1.43]CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020448%1,417moderatenot evaluable clinical improvement (time to event analysis only)detailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] GS-US-540-5773 (Goldman), 2020 (REV) 1.27 [0.98; 1.63] GS-US-540-5774, 10 days, 2020 1.16 [0.94; 1.44] GS-US-540-5774, 5 days, 2020 1.15 [0.93; 1.42] NIH NIAID ACTT-1, 2020 1.29 [1.12; 1.49] 1.23[1.12; 1.35]CAP-China (Wang et al.), 2020, GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 202050%2,492moderatenot evaluable death or ventilationdetailed resultsSOLIDARITY (remdesivir), 2020 0.97 [0.85; 1.10] 0.97[0.85; 1.10]SOLIDARITY (remdesivir), 202010%5,451NAnot evaluable mechanical ventilationdetailed resultsGS-US-540-5774, 10 days, 2020 0.26 [0.03; 2.30] GS-US-540-5774, 5 days, 2020 0.13 [0.01; 2.45] Mahajan, 2021 2.27 [0.39; 13.27] SOLIDARITY (remdesivir), 2020 1.04 [0.87; 1.23] 0.87[0.39; 1.96]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, Mahajan, 2021, SOLIDARITY (remdesivir), 2020429%5,818moderatenot evaluable recoverydetailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 1.23 [0.97; 1.57] GS-US-540-5774, 10 days, 2020 1.11 [0.90; 1.37] GS-US-540-5774, 5 days, 2020 1.18 [0.96; 1.45] 1.17[1.03; 1.33]GS-US-540-5773 (Goldman), 2020 (REV), GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202030%1,193moderatenot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233NAnot evaluable serious adverse eventsdetailed resultsCAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] GS-US-540-5774, 10 days, 2020 0.55 [0.25; 1.23] GS-US-540-5774, 5 days, 2020 0.50 [0.22; 1.14] NIH NIAID ACTT-1, 2020 0.72 [0.54; 0.96] 0.67[0.53; 0.85]CAP-China (Wang et al.), 2020, GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 2020, NIH NIAID ACTT-1, 202040%2,080moderatenot evaluable adverse eventsdetailed resultsGS-US-540-5774, 10 days, 2020 1.63 [1.09; 2.42] GS-US-540-5774, 5 days, 2020 1.21 [0.82; 1.80] 1.40[1.05; 1.87]GS-US-540-5774, 10 days, 2020, GS-US-540-5774, 5 days, 202024%784moderatenot evaluable deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.64 [0.23; 1.81] 0.62[0.23; 1.64]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] NIH NIAID ACTT-1, 2020 0.67 [0.38; 1.18] 0.58[0.34; 0.97]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202026%1,296moderatenot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] NIH NIAID ACTT-1, 2020 0.84 [0.30; 2.34] 0.97[0.48; 1.93]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296lownot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] NIH NIAID ACTT-1, 2020 0.96 [0.19; 4.80] 0.82[0.20; 3.29]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] NIH NIAID ACTT-1, 2020 1.02 [0.64; 1.61] 1.02[0.64; 1.61]CAP-China (Wang et al.), 2020, NIH NIAID ACTT-1, 202020%1,296moderatenot evaluable serious adverse events (SAE), anydetailed resultsGS-US-540-5773 (Goldman), 2020 (REV) 1.98 [1.27; 3.11] 1.98[1.27; 3.11]GS-US-540-5773 (Goldman), 2020 (REV)10%397NAnot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-11-01 00:06 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 510 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons